genedrive, an emerging UK medtech company, focuses on the development and commercialization of an innovative, point-of-care diagnostic system, also called Genedrive® (in this report, "genedrive" refers to the company, whereas "Genedrive®" indicates the product). genedrive is poised to become the first company to launch a decentralized Hepatitis C diagnostic, entering a large market at a time when new curative therapies for the disease are transforming opportunities for testing and treatment. A Genedrive® TB diagnostic has already been launched and the platform has a wide range of alternative applications.
15 Jun 2017
Genedrive -Ready to launch the first point-of-care HepC test
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Genedrive -Ready to launch the first point-of-care HepC test
Genedrive Plc (GDR:LON) | 5.8 0 (-2.1%) | Mkt Cap: 8.23m
- Published:
15 Jun 2017 -
Author:
Dr. Riccardo Lowi -
Pages:
4
genedrive, an emerging UK medtech company, focuses on the development and commercialization of an innovative, point-of-care diagnostic system, also called Genedrive® (in this report, "genedrive" refers to the company, whereas "Genedrive®" indicates the product). genedrive is poised to become the first company to launch a decentralized Hepatitis C diagnostic, entering a large market at a time when new curative therapies for the disease are transforming opportunities for testing and treatment. A Genedrive® TB diagnostic has already been launched and the platform has a wide range of alternative applications.